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Background: Metabolic syndrome (MS) is a condition associated with obesity that identifies individuals with
increased cardiovascular risk. Gastric bypass improves several MS components, such as glucose, lipid metabolism
and hypertension. The aim of this study was to evaluate the effect of long-limb gastric bypass on the remission of
MS criteria associated with morbid obesity.
Methods: Obese patients who met the “harmonized” criteria for MS (n = 153) that underwent laparoscopic
Roux-en-Y gastric bypass (LRYGB) with a long biliopancreatic limb were prospectively evaluated with regards to
body weight, body mass index (BMI), percentage of excess BMI lost (% EBMIL), fasting glucose, blood pressure and
lipid profile up to 36 months after surgery.
Results: Before surgery, patients had a BMI of 44.3 ± 0.5 kg/m2; 66% were under anti-diabetic treatment; 78.4% were
under anti-hypertensive treatment and 44.3% were under anti-dyslipidemic treatment. After a mean follow-up time
of 2.4 ± 0.1 years, MS remission rates were 32.7% at 6 months, 69.7% at 12 months, 63.4% at 24 months, and 59.2%
at 36 months; when only 32.9%, 43.4% and 15.8% of patients were still under anti-diabetic, anti-hypertensive and
anti-dyslipidemic treatment, respectively. The %EBMIL and BMI were the parameters that showed the highest
accuracy to predict the MS remission at all-time points after the surgery.
Conclusions: Long limb gastric bypass in obese patients results in significant and sustained weight loss which
predicts a high remission rate of MS and allows the discontinuation of drug therapy for several metabolic
disturbances in most patients.
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Obesity has assumed alarming worldwide proportions in
the last decades [1,2]. The number of overweight and
obese persons has been estimated to encompass 1.7
billion individuals [3]. Obesity and related co-morbidities
affect both patients quality of life and life expectancy
[4]. The rise in the rate of obesity has been associated
with an increased incidence of many obesity-related co-
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reproduction in any medium, provided the orlipid disorders and hypertension, which are major
causes of cardiovascular diseases [5-8]. Obesity and
overweight are responsible for the increased risk of
mortality due to cardiovascular disease, particularly in
the presence of visceral adiposity, a key component in
the development of insulin resistance [9] and metabolic
syndrome (MS) that has become an important public
health concern [10,11].
The first descriptions of the association between
T2DM, hypertension and dyslipidemia dates from 1920;
but it was Reaven in 1988, who suggested for the first
time that these factors tended to occur in the same indi-
vidual under the form of a syndrome “X”, which included
five components: resistance to glucose uptake mediated byd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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glycerides, decreased HDL cholesterol and hypertension;
all five components were associated with an increased risk
of coronary heart disease [12]. In 1998, a WHO advisory
group proposed the designation and suggested the first
working criteria for MS [13], while later other definitions
have been proposed by NCEP- ATPIII (National Cholesterol
Education Program - Adult Treatment Panel III, 2001),
IDF (International Diabetes Federation, 2005) and more
recently the “Harmonized” Criteria [14].
The prevalence of MS varies with age and sex, studied
population and criteria used for its definition. The preva-
lence of MS in the U.S. varies; between 40–59 years is 40%
in men and 34% women, while aging is accompanied by a
20% increase in the prevalence of MS [11,15,16]. In high-
risk populations, such as relatives of diabetic patients the
prevalence of MS increases to 50%; in diabetic patients to
80% and individuals in with impaired glucose tolerance to
40% [15]. In Europe, the reported prevalence of MS is
9.5% in men and 8.9% in women, based on the DECODE
study, [17]; while 24% of the adult population in the
northern region of Portugal meet the ATPIII criteria for
MS [18].
Insulin resistance is considered the central abnormally
of MS and T2DM, preceding the disease diagnosis and
clinical findings in 5 to 6 years; MS increases the lifetime
risk of developing T2DM and is associated with a higher
prevalence of cardiovascular disease and cardiovascular
death [19], which justify the main interest in identifying
patients with MS [20].
At the present time there is no single medication that
targets MS. Lifestyle modifications with the aim of redu-
cing the underlying causes: central obesity/overweight
and insulin resistance are the cornerstones in the
management of MS [21,22]. Aggressive treatment with
drug combination therapy targeted to each of the
components of the MS is highly recommended as the
benefits are well-known in the control on morbidity
and mortality [23].
Since most dietary interventions do not achieve more
than 10-15% weight loss that is often regained, the med-
ical treatment of obesity and MS rarely allows long last-
ing or sustained weight loss and MS remission. Bariatric
surgery, as a treatment option for obese individuals, has
proven to be effective in treating the different compo-
nents of the MS, as well inducing a significant reduction
in the prevalence of MS [22,24,25].
After having demonstrated that LRYGB with a 200 cm
biliopancreatic limb in obese patients was associated
with a high remission rate of diabetes and improvement
of the metabolic control [26], the purpose of the current
study was to evaluate the efficacy and safety of the same
surgical technique when applied for the treatment of
obese patients with metabolic syndrome.Methods
Patients and methods
Obese individuals were selected from the prospective
database of patients referred for bariatric surgery at the
Department of General Surgery of Centro Hospitalar de
Entre o Douro e Vouga (CHEDV), Portugal. The database
included 696 patients that underwent laparoscopic gastric
bypass, of which 153 patients met diagnostic criteria for
MS and were submitted to LRYGB for the primary
treatment of obesity.
The inclusion criteria were BMI > 35 kg/m2 with diag-
nostic criteria of MS according to the “harmonized” cri-
teria, consisting in the presence of three abnormal
findings out of the following five: abdominal obesity ≥
102 cm (men) or ≥ 88 cm (women) caucasians; hyper-
tension ≥ 130/85 mmHg; high triglycerides ≥ 150 mg/dl;
low HDL <40 mg/dl (men) or <50 mg/dl (women); fast-
ing glucose ≥ 100 mg/dl, or drug treatment for any of
these conditions [14]. For abdominal obesity, since the
recommended cut points equate to a body mass index
of approximately 30 kg/m2 according to the definitions
of abdominal obesity found in National Institutes of
Health obesity guidelines, and as the location of the
waist is often difficult to determine rendering the measure
less accurate, a BMI > 30 Kg/m2 was used as a surrogate
marker for visceral obesity [14,21].
Every patient with MS criteria proposed for bariatric
surgery for the treatment of obesity during this period of
time was enrolled in the study and submitted to LRYGB
with a bilio-pancreatic limb of 200 cm as previously de-
scribed [26]. Subjects were informed of potential risks
associated with the surgery and signed an informed con-
sent document, which was approved by the (CHEDV)
Institutional Ethical Review Board.
The parameters evaluated in patient follow-up were
body weight, BMI, percentage of excess BMI lost (%
EBMIL), fasting blood glucose, blood pressure and lipid
profile up to 36 months after surgery and ongoing medical
treatment before and after surgery. The patients were
assessed for the presentation of MS parameters at each
time point of the study and no time limit has been defined
for normalization of the metabolic parameters. Patients
were classified as being in remission if no longer had diag-
nostic criteria of MS.Statistical analysis
Results are presented as mean ± standard error of the
mean (Mean ± SEM) unless otherwise specified. Compari-
sons between groups were performed with the Kruskal–
Wallis test (one-way ANOVA) followed by the Dunn post
hoc test. Ordinal and nominal data were compared using
a Chi square test and s p <0.05 was considered significant.
To test the accuracy of all parameters in predicting the
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receiver operating characteristic (ROC) curve. Based
on the area under the curve (AUC), the test is consid-
ered excellent when the AUC is 0.90 to 1.00; good from
0.80 to 0.90; fair from 0.70 to 0.80; poor from 0.60 to
0.70 and fail if below 0.60. Data was analyzed using the
IBM SPSS Statistics 21 and Graphpad Prism 5.04
programs.Results
Patients enrolled in the study (n = 153) included 84.3%
of females (n = 129) and 15.7% males (n = 24) with a
mean age of 48.5 ± 0.7 years and a mean BMI of 44.3 ±
0.5 kg/m2 at the time of the surgery. All patients met at
least three diagnostic criteria for MS; thus, 66.0% (n = 101)
were under anti-diabetic drugs, 78.4% (n = 120) were
treated for hypertension and 44.3% (n = 66) were treated
for dyslipidemia. The mean follow-up time after surgery
was 2.4 ± 0.1 years, and every patient included in the
statistical analysis had a minimum follow-up time of 6
months (Table 1).
After the surgery, there was a significant reduction
in BMI and increase in the percentage excess of BMI
lost from 6 months onwards. The BMI was reduced to
32.7 ±0.4 kg/m2 at 6 months, reaching its maximum at
12 months (30.8 ±0.4 kg/m2), and was followed by a
non-significant increase to 31.2 ± 0.5 kg/m2 and 32.2 ±
0.7 kg/m2 at 24 and 36 months, respectively. The percent-
age excess of BMI lost increased after the surgery from
63.5 ± 1.5% at 6 months, to 73.4 ± 1.7% at 12 months,
followed by a non-significant decrease to 71.6 ± 1.8% at 24
months and 67.8 ± 2.4% at 36 months of follow-up. There
was also a significant improvement of all analytical param-
eters used in the diagnosis of MS, namely a decrease of
fasting glucose, systolic and diastolic blood pressure, and
triglycerides, as well as an increase in HDL-cholesterol
levels. Along with weight loss and improvement of meta-
bolic profiles, the need of medical treatment for those
conditions decreased while the discontinuation of drug
use increased gradually over time, reaching maximumTable 1 Patient demographics and length of follow-up
Patient characteristics at baseline Number
Age (years) 48.5 ± 0.7
Male/Female 24.0:129.0 (15.7%:84.3%)
Body Weight (kg) 113.9 ± 1.4
BMI (Kg/m2) 44.3 ± 0.5
Under anti-diabetic treatment 101.0 (66.0%)
Under anti-hypertensive treatment 120.0 (78.4%)
Under anti-dyslipidemic treatment 66.0 (44.3%)
Mean follow-up time (years) 2.4 ± 0.1levels at 24 months of follow-up. The discontinuation rate
of the use drugs at 36 months after surgery was 51.2% for
anti-diabetics, 44.6% for anti-hypertensives and 64.3% for
anti-dyslipidaemic drugs (Table 2).
The number of patients that met diagnostic criteria
for MS decreased gradually and significantly after the
gastric bypass surgery, the remission rate of MS was
32.7% (n = 103) at 6 months, 69.7% (n = 43) at 12 months,
followed by a non-significant increase to 63.4% (n = 41) at
24 months and to 59.2% (n = 31) at 36 months after sur-
gery (Table 2). The prevalence of MS in our population of
patients submitted to bariatric surgery was 22% before
surgery and decreased to 4.4% 36 months after gastric
bypass.
The parameters that showed the highest accuracy to
predict the MS remission in all time points (6 months, 1
year, 2 years and 3 years) were the %EBMIL and the BMI,
with AUC between 0.75-0.85, which denotes that these
parameters are either fair or good in predicting MS. The
HDL levels also showed a good accuracy (AUC = 0.80) in
predicting MS remission but only in the second year after
surgery. The cut-off points of BMI that better defined the
resolution of MS were: <30.92 kg/m2; <29.74 kg/m2;
<29.92 kg/m2 and <31.24 kg/m2, for 6 months, 1 year,
2 years and 3 years follow-up, respectively, or <30.02 kg/m2
when considering all time points. The cut-off points
of EBMIL that better defined the resolution of MS
were: > 68.28%; > 76.89%; > 75.45% and > 69.89%, for 6
months, 1 year, 2 years and 3 years follow-up, respectively,
or >66.08% considering all time points. The cut-off
point of HDL that better defined the resolution of MS
was > 58.50 mg/dL at 2 years after the surgery.
The morbidity associated with the surgical procedure
included a major early complications rate of 12.4% (n = 14),
which included gastrojejunal anastomosis fistulas 2.6%
(n = 4), gastrojejunal anastomosis leaks 5.8% (n = 9), hypo-
volemic shock 0.65% (n = 1), small bowel perforation
0.65% (n = 1), intra-abdominal abscess 1.9% (n = 3), and
perforation of the abdominal esophagus 0.65% (n = 1); and
major late complications rate of 1.9% (n = 3). Late minor
complications rate was of 35% (n = 53) and included
mostly anemia due to iron, folate or vitamin B12 defi-
ciencies that has arose in spite of systematic prescrip-
tion of broad-spectrum vitamin supplementation. The
rate of surgical re-intervention was of 4.5% (n = 7) and
the 30 days the mortality rate was of 0.65% (n = 1)
(Table 3).Discussion
Weight loss is the primary goal in the treatment of MS,
as lifestyle intervention with a modest weight loss has
showed to reduce the prevalence and the incidence of
MS [27,28].
Table 2 Metabolic syndrome remission rate and metabolic profile
Follow-up time (months) 0 6 12 24 36 P
Patients n = 153 (100%) n = 153 (100%) n = 142 (93%) n = 112 (73%) n = 76 (50%) n.a
BMI (kg/m2) 44.3 ± 0.5 32.7 ± 0.4***(a) 30.8 ± 0.4***(a) 31.2 ± 0.5***(a) 32.2 ± 0.7***(a) < 0.001
EBMIL (%) - 63.5 ± 1.5***(a) 73.4 ± 1.7***/**(a/b) 71.6 ± 1.8***/*(a/b) 67.8 ± 2.5***(a) < 0.001
Patients with MS 153 103 43 41 31 n.a
MS remission rate (%) 0.0 32.7***(a) 69.7***/***(a/b) 63.4%***/***(a/b) 59.2%***/***(a/b) (a),(b)p < 0.001
Fasting glycemia (mg/dL) 136.4 ± 4.8 95.0 ± 2.4***(a) 90.4 ± 1.1***(a) 93.7 ± 1.6***(a) 93.8 ± 1.9***(a) < 0.001
Systolic blood pressure (mm Hg) 147.2 ± 1.5 140.4 ± 1.7*(a) 138.3 ± 1.5***(a) 139.0 ± 1.7**(a) 143.9 ± 2.0 < 0.001
Diastolic blood pressure (mm Hg) 88.4 ± 1.0 82.5 ± 1.0***(a) 81.6 ± 1.0***(a) 81.9 ± 1.0***(a) 82.7 ± 1.4***(a) < 0.001
HDL (mg/dL) 45.5 ± 0.8 44.8 ± 1.0 52.0 ± 0.9***/***(a/b) 56.5 ± 1.0***/***/*(a/b/c) 56.4 ± 1.6***/***(a/b) < 0.001
Triglycerides (mg/dL) 171.7 ± 7.4 104.0 ± 3.2***(a) 94.5 ± 3.3***(a) 100.7 ± 5.0***(a) 104.6 ± 5.4***(a) < 0.001
Anti-diabetic treatment 101 (66.0%) 33 (22.8%)***(a) 28 (19.9%)***(a) 32 (28.6%)***(a) 25 (32.9%)***/*(a/c) (a)p < 0.001
(c)p = 0.046
Anti-hypertensive treatment 120 (78.4%) 59 (40.7%)***(a) 50 (35.7%)***(a) 41 (36.9%)***(a) 33 (43.4%)***(a) < 0.001
Anti-dyslipidemic treatment 66 (44.3%) 13 (9.0%)***(a) 13 (9.4%)***(a) 12 (10.8%)***(a) 12 (15.8%)***(a) < 0.001
*p < 0.05; **p < 0.01; ***p < 0.001; (a) vs baseline; (b) vs 6 months; (c) vs 1 year. Kruskal–Wallis test (one-way ANOVA) with Dunn post hoc test for scale data and
Chi Square test for ordinal data.
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a significant reduction in BMI and increase in %EBMIL
from 6 months after the surgery onwards. The %EBMIL
after the surgery increased from 6 months to 12 months,
which was followed by a non-significant decrease at 24
months and at 36 months of follow-up, but remaining wellTable 3 Morbidity, surgical re-intervention and mortality
rate of gastric bypass
Complication Number of patients %
Early major complications
Gastrojejunal anastomosis fístula 4 2.6
Gastrojejunal anastomosis leak 9 5.8
Hypovolemic shock 1 0.7
Small bowel perforation 1 0.7
Intra-abdominal abcess 3 1.9
Perforation of the abdominal esophagus 1 0.7
TOTAL 12.4
Late major complications
Anatomotic stenosis 2 1.3
Vitamin B1deficiency 1 0.7
TOTAL 2
Late minor complications
Anemia 54 35
Iron deficiency 23 15
Vitamin B12deficiency 52 33
Folate deficiency 12 7.8
Rate of surgical re-intervention 7 4.5
30 days mortality 1 0.7above 60%. After the surgery there was a significant
improvement in all parameters of the MS “harmonized”
criteria, as well as a large discontinuation rate of anti-
diabetic, anti-hypertensive and anti-dyslipidemic drug use.
The maximum remission rate of MS occurred at 12
months, just as the %EBMIL. Although the maximum
remission rate of some individual components of the MS
occurred at 36 months, namely T2DM, the same was not
found in relation to MS criteria. Despite the increase in
length of the biliopancreatic limb, the rates of nutritional
deficits were lower than those reported by other series
which have used the conventional bypass technique, since
the length of the common channel in our technical
modification is shorter or not different from other stud-
ies, which is the major determinant of malabsorption
with a higher potential to impact over the nutritional
status [29,30].
Surgical therapy is currently the only treatment for
severe obesity that has proved to be effective in the
long-term [5]. Bariatric surgery has been demonstrated
to be safe and induce the remission of co-morbidities
associated with obesity beyond weight reduction [7].
LRYGB has demonstrated to reduce the risk of developing
T2DM by approximately 75% [31], induce euglycemia in
83% of patients with impaired fasting glucose or T2DM
with a higher probability in patients with the shortest
duration and mildest form of T2DM [32], reduce blood
pressure, mostly in patients with a shorter preoperative
duration of the co-morbid condition [33] and improve
abnormal lipid levels [34].
In a previous study from our group, T2DM patients
submitted to LRYGB with a long biliopancreatic limb
showed high remission rates the disease of 87.9% at 6
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follow-up and an improvement of metabolic control in
those that remained diabetic [26]. Pinheiro et al., had
also reported an improved resolution of diabetes despite
similar weight loss, in super-obese patients submitted to
LRYGB with a biliopancreatic limb of 100 cm, compared
to the gastric bypass with 50 cm biliopancreatic limb
[35], suggesting metabolic benefits of this surgical
modification.
Since the improvement of the different components of
metabolic syndrome after weight loss has been widely re-
ported, bariatric surgery should be considered an alterna-
tive therapy for MS patients with BMIs above 35 kg/m2
[31,36,37], and possibly emerging treatment for patients
with BMIs below 35 kg/m2 [38].
The prevalence and remission of MS before and
after bariatric surgery, has been described before,
however, most studies included small patient sam-
ples, had a short follow-up time after surgery, there
was no uniformity with regards to the definition MS
used and no variable was found to predict resolution
of MS. Therefore, the remission rate of MS varies
with the criteria used for diagnosis and consequently
it is difficult to compare the results between different
studies [22,24,39-41].
The prevalence of MS has been shown to decrease sig-
nificantly from 83.2% to 98.4% after surgery [22,24,39,40].
In a large controlled study from the Mayo Clinic with a
mean follow-up time of 40 months that included 180
patients submitted to LRYGB and 157 patients enrolled
in a medical weight-reduction program, showed that
prevalence of MS decreased from 87% to 29% in the
bariatric surgery group and from 85% to 75% in the
non-surgical group, as defined by the American Heart
Association [21].
In the only long term study of the evolution of MS after
different bariatric surgery techniques- vertical banded
gastroplasty, LRYGB and biliopancreatic diversion- the
authors showed that at 12 months after surgery all pro-
cedures were responsible for a similar remission rates of
MS, using the IDF classification. However, when revalu-
ated at 7 years of follow-up, the percentage of patients
submitted to vertical banded gastroplasty and LRYGB
that presented MS resumed to near preoperative values
owing to weight regain, which did not occur after biliopan-
creatic diversion yet at the expense of a higher morbidity
rate [42].
Most previous reports of MS remission after bariatric
surgery have used the WHO or the NCEP criteria,
which do not include pharmacological therapy as MS
criteria, therefore the use of the IDF and “harmonized”
definitions of the metabolic syndrome lead to a higher
prevalence of the metabolic syndrome [10], which could
account for the higher prevalence of MS found in ourpost-surgical patients. To our knowledge, no previous
study on bariatric patients has used the most updated
“harmonized” diagnosis criteria for MS.
The proposed mechanisms that could explain the effi-
cacy of bariatric surgery in the reversibility of MS include
weight loss, the decrease in food intake, reduction of
abdominal obesity and insulin resistance, reduction in
fatty acid turnover, amelioration of the inflammatory
response and improvement of endothelial function [1,43,44].
Changes in incretin hormones after the surgical procedures
may have a role that still requires being further investigated
and could account specifically for the better results achieved
after gastric bypass compared to restrictive procedures in
diabetes remission. Our data showed that the %EBMIL
and BMI were the best parameters for predicting MS
remission, suggesting that in contrast to what is observed
regarding diabetes, weight loss is a major determinant of
MS remission in the clinical setting, as supported by previ-
ous studies [21]. The %EBMIL has been shown to be the
best parameter to predict MS improvement in obese sub-
jects after Roux-en-Y gastric bypass [45], while the reso-
lution of MS was demonstrated to be independent of
preoperative BMI [46].
Conclusion
MS associated with obesity is reversible by weight loss
attained through bariatric surgery. Long limb LRYGB in
obese patients is a safe procedure that results in significant
and sustained %EBMIL, which predicts a high remission
rate of MS and allows discontinuation of drug therapy for
associated metabolic disturbances.
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